

Docket No: 22058-590 DIV CON (GI005291)

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Herrmann et al.

Application No.: 10/614,475 Examiner: Parithosh K. Tungaturthi

Filed: July 7, 2003 Art Unit: 1643

For: Chimeric Polypeptides Containing Chemokine Domains

Customer Number: 30623

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

TERMINAL DISCLAIMER

I, Thomas S. Szatkowski, represent that I am empowered to act on behalf of Genetics Institute, LLC. Genetics Institute, LLC is the assignee of record, Recordation of Assignment Reel Number/ Frame 8554/0387 and Reel/Frame 012772/0631, of the entire right, title, and interest in and to the invention in the subject application. Genetics Institute, LLC is also the assignee of record of U.S. Patent No. 6,730,296, Recordation of Assignment Reel Number/ Frame 8554/0387 and Reel/Frame 012772/0631.

On behalf of Genetics Institute, LLC, I hereby disclaim, except as otherwise provided herein, the terminal part of any patent granted on the subject application which would extend beyond the expiration date of the full statutory term, including statutory extensions thereof of U.S. Patent No. 6,730,296, except to the extent that the term of this application Application No. 10/614,475, might be extended pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (35 USC §156) or any other applicable act of Congress, and hereby agree that any patent so granted on the subject application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,730,296, this agreement to run with any patent granted on the subject application and to be binding upon the grantee, its successors or assigns.

Genetics Institute, LLC, does not disclaim any terminal part of any patent granted on the subject application prior to the expiration date of the full statutory term of U.S. Patent No. 6,730,296 in the event that such patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a); has all claims cancelled by a reexamination certificate; is reissued; or is otherwise terminated prior to the expiration of its statutory term, except for the separation of legal title stated above.

Pursuant to 37 CFR 3.73(b), I have reviewed all the recordation information above or all documents in the chain of title of the subject patent application and, to the best of my knowledge and belief, title is in the assignee identified above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Docket No: 22058-590 DIV CON (GI005291)
Patent

Payment of the requisite fee of \$130.00 is enclosed. Please charge any additional fees that may be due, or credit any overpayment of the same, to Deposit Account No. 50-0311, (Reference No. 22058-590 DIV CON). A duplicate copy of the transmittal letter is enclosed.

Date: September 28, 2007

Thomas S. Szatkowski Assistant Secretary, Wyeth

Reg. No. 28,049

Patent Law Department Five Giralda Farms Madison, NJ 07940 Tel. No. (617) 665-6163

4023860v.1